Eclipse Diagnostics, a new diagnostics subsidiary of Large Scale Biology that plans to market mass spec-based pattern recognition technology, announced its management team last week:
Kevin Ryan, president and CEO of LSBC, will become Eclipse’s president. He holds a bachelor’s degree in business and marketing from the University of Notre Dame. John Rakitan will be senior vice president and general manager, in addition to being senior vice president, general counsel, and secretary at LSBC. Rakitan holds a JD from the University of Notre Dame and a BS in biology from Northern Illinois University. Gary Wolfe will serve as senior vice president and CSO. He has been working for LSBC since 1999. Wolfe received a BS in chemistry from the University of California, Los Angeles, and a PhD in physical chemistry from the University of Washington. Guy della Cioppa will be senior vice president for business development. He joins Eclipse from NanoInk, where he was executive vice president of business development. He holds a PhD in biology from the University of California, Los Angeles.; Ronal Artale will become senior vice president and CFO. He is also senior vice president, COO, and CFO at LSBC. Artale holds an MBA in finance from St. John’s University.
In addition, John Chute has been appointed to Eclipse’s scientific advisory board. He is a medical oncologist and hematologist and an associate professor at the Duke University Medical Center. Prior to that, he was vice president for medical affairs at LSBC. Chute holds an undergraduate degree from the University of Notre Dame and a medical degree from Georgetown University School of Medicine.
Thomas Schweins has become vice president for corporate strategy at Qiagen. He joins the company from The Boston Consulting Group, where he was a manager based in Germany. Schweins holds a PhD from the Max Planck Society, an MSc in business administration and chemistry from the University of Southern California, Los Angeles, and an undergraduate degree in biochemistry from the University of Hanover in Germany.
Douglas Powell has become director of immunobiology at Antigen Express, a subsidiary of Generex Biotechnology. He joins the company from Millennium Pharmaceuticals, where he was a senior scientist. Powell holds a PhD in genetics from George Washington University.
Vaughn Kailian has become chairman of the board of Cambridge, Mass.-based Elixir Pharmaceuticals, the company said today. He is also vice chair of the board of directors of Millennium Pharmaceuticals. Prior to joining Millennium, he was CEO of COR Therapeutics until it was acquired by Millennium.